ClinicalTrials.gg
Not yet recruitingNCT07945483BUBBLE-PEPUpdated Nov 18, 2026

Effects of Bubble-PEP After Open Heart Surgery on Blood Gases, Dyspnea, Secretion Status, and Pain

An interventional study of Bubble Positive Expiratory Pressure (Bubble-PEP) Therapy in Cardiac Surgery and Open Heart Surgery, sponsored by Afyonkarahisar Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Afyonkarahisar Health Sciences University · Not applicable, Interventional, and Supportive care

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 84 studies in Dyspnea with a site in Turkey — 17 open to participants now, 20 under way, none of them phase 3. Dyspnea · Turkey.

Planned enrollment
13th of 60
92 · median 60
Started
2026
with 8 others
No phase
58 of 84
12 open now
Primary completion
2027-04
later than 17 of 19 live
Registered
84th of 84
by date

Among the 84 studies in Dyspnea with a site in Turkey, this one is the 13th largest by planned enrollment of the 60 interventional ones that give a count, is one of 9 that started in 2026, is one of 58 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 84th registered.

Dyspnea

893 studies on the registry are indexed under Dyspnea; 188 are open to participants now.

Browse Dyspnea studies →

Open to participants now

17 of the 84 studies in Dyspnea with a site in Turkey are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 126 Dyspnea studies recruiting now, 69 (55%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Dyspnea with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled study aims to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain in patients undergoing open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. A total of 92 adult patients undergoing coronary artery bypass grafting or heart valve surgery will be included. Participants will be randomly assigned to an intervention group (n=46) or a control group (n=46) using stratified block randomization based on surgical procedure.

Both groups will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry. In addition to standard care, the intervention group will receive Bubble-PEP therapy twice daily for three consecutive days following extubation. Each session will consist of three sets of 10 expirations.

Arterial blood gas parameters, dyspnea, respiratory secretion status, and pain will be assessed at baseline, during follow-up, and after completion of the intervention. Patient satisfaction will also be evaluated.

The study aims to determine whether adding Bubble-PEP therapy to standard postoperative care improves respiratory outcomes and contributes to evidence-based nursing care following open-heart surgery.

Read the detailed description

Study Design and Setting This study is designed as a randomized controlled trial to investigate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain following open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. Ethical approval was obtained from the Non-Interventional Scientific Research Ethics Committee of Afyonkarahisar Health Sciences University on October 2, 2026 (Decision No. 740).

Participants and Sample Size The study will include 92 adult patients undergoing coronary artery bypass grafting (CABG) or heart valve surgery, with 46 patients assigned to each group.

The sample size was calculated using G*Power 3.1.9.7, based on an effect size of 0.659 for PaO2, a significance level of 0.05, and 80% statistical power. The initial sample size was 76 participants, which was increased to 92 to account for an anticipated 20% dropout rate.

Eligible participants will be aged 18 years or older, have undergone CABG or heart valve surgery, be extubated and hemodynamically stable, be able to communicate in Turkish, and provide informed consent.

Randomization and Blinding Participants will be allocated to intervention and control groups in a 1:1 ratio using stratified block randomization according to surgical type (CABG or heart valve surgery).

Computer-generated randomization lists will be prepared by an independent researcher who is not involved in intervention delivery or outcome assessment. Group allocation will be implemented using sequentially numbered, sealed envelopes.

Due to the nature of the intervention, participants and the researcher administering Bubble-PEP therapy cannot be blinded. However, outcome assessments will be conducted by an independent assessor blinded to group allocation. The statistician will also remain blinded to group identity until completion of the analysis.

Control Group Participants in the control group will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry.

Intervention Group Participants in the intervention group will receive Bubble-PEP therapy in addition to standard postoperative care.

The Bubble-PEP apparatus will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and a tube approximately 80 cm long with an internal diameter of 8 mm. A separate bottle and tube will be provided for each participant.

Bubble-PEP therapy will begin after extubation, once the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.

During the intervention, patients will be placed in an upright sitting position and instructed to inhale deeply through the nose and then exhale slowly, continuously, and in a controlled manner through the tube submerged in water.

The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

Outcome Measurements

The primary outcome measures will include:

Arterial blood gas parameters: PaO2, PaCO2, pH, HCO3-, base excess (BE), and oxygen saturation (SpO2).

Dyspnea severity assessed using the Modified Borg Dyspnea Scale. Respiratory secretion status and cough effectiveness assessed using a researcher-developed postoperative respiratory secretion and cough effectiveness assessment form.

Secondary outcome measures will include:

Pain intensity assessed using the Visual Analog Scale (VAS). Patient satisfaction assessed using a visual patient satisfaction scale.

Data Collection and Assessment Schedule Preoperative demographic and clinical data will be collected after obtaining written informed consent. Preoperative dyspnea and pain assessments will also be performed.

The first calendar day following extubation will be designated as Day 1 (G1). Baseline postoperative assessments will be performed on Day 1, before the first Bubble-PEP session, preferably between 09:00 and 10:00, provided that at least six hours have elapsed since extubation and the patient is hemodynamically stable.

Follow-up assessments will be performed on Days 2 and 3 (G2 and G3), between 09:00 and 10:00, before the daily intervention.

The final assessment will be performed on Day 4 (G4), between 09:00 and 10:00, following completion of the three-day intervention period. Patient satisfaction will also be evaluated during the final assessment.

Arterial blood gas results obtained as part of routine clinical care will be recorded from patient records.

Statistical Analysis Data will be analyzed using SPSS software. Descriptive statistics will include frequencies, percentages, means, and standard deviations.

Depending on the distribution of the data, independent-samples t-tests or Mann-Whitney U tests will be used for between-group comparisons. Paired t-tests or Wilcoxon signed-rank tests will be used for within-group comparisons.

Repeated-measures analysis of variance or Friedman tests will be used to evaluate changes over time, as appropriate. Exploratory subgroup analyses based on surgical type may be performed if the sample size is sufficient.

Statistical significance will be set at p \< 0.05.

03

Conditions studied

  • Cardiac Surgery
  • Open Heart Surgery

Browse trials for

Keywords

  • open-heart surgery
  • Bubble PEP
  • Arterial Blood Gas
  • Dyspnea
  • Secretion Status
  • Pain
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having undergone Coronary Artery Bypass Graft (CABG) or heart valve surgery,
  • Being 18 years of age or older,
  • Not having undergone postoperative revision surgery,
  • Having no neurological or severe cognitive impairment, and no postoperative delirium,
  • Being extubated and hemodynamically stable,
  • Being able to communicate in Turkish,
  • Being willing to participate in the research.

Exclusion criteria

Exclusion Criteria:

  • Having undergone a surgical procedure other than CABG or heart valve surgery,
  • Patients who require revision surgery during the postoperative period,
  • Patients with neurological or severe cognitive impairment,
  • Patients experiencing postoperative delirium,
  • Individuals aged 18 years or younger,
  • Patients who have not been extubated,
  • Patients who are hemodynamically unstable,
  • Individuals with whom it is not possible to communicate in Turkish, or those who are unwilling to participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Bubble-PEP Intervention Group

    Patients in the intervention group will receive Bubble Positive Expiratory Pressure (Bubble-PEP) therapy in addition to routine postoperative care following open-heart surgery. I will evaluate the intervention's effects on arterial blood gas parameters, dyspnea, secretion status, and pain.

    Device: Bubble Positive Expiratory Pressure (Bubble-PEP) Therapy

  • No intervention
    Control Group

    Patients in the control group will receive routine postoperative care following open-heart surgery, with no additional interventions applied. I will assess arterial blood gas parameters, dyspnea, secretion status, and pain.

Interventions

  • DeviceBubble Positive Expiratory Pressure (Bubble-PEP) Therapy

    A researcher-prepared Bubble Positive Expiratory Pressure (Bubble-PEP) device will be used in addition to standard postoperative care. The device will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and an approximately 80-cm-long tube with an internal diameter of 8 mm. Each patient will be provided with an individual bottle and tube. Bubble-PEP therapy will be initiated after extubation when the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician. During the intervention, the patient will be placed in an upright sitting position and instructed to inhale deeply through the nose, followed by slow, controlled, and continuous exhalation through the tube submerged in water. The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

    Also known as: Bottle Positive Expiratory Pressure (Bottle-PEP)

06

What researchers measure

Primary outcomes

  1. Change in Arterial Oxygen Partial Pressure(PaO₂)

    Arterial oxygen partial pressure(PaO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  2. Change in Arterial Carbon Dioxide Partial Pressure(PaCO₂)

    Arterial carbon dioxide partial pressure (PaCO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaCO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  3. Change in Arterial Blood pH

    Arterial blood pH will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in arterial blood pH will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  4. Change in Arterial Oxygen Saturation (SaO₂)

    Arterial oxygen saturation (SaO₂, %) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in SaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  5. Change in Arterial Bicarbonate Level (HCO₃-)

    Arterial bicarbonate levels (HCO₃-, mmol/L) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in HCO₃- levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  6. Change in Arterial Blood Base Excess (BE)

    Arterial blood base excess (BE, mmol/L) will be assessed using arterial blood samples obtained from patients following open-heart surgery. Changes in BE levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

  7. Change in Dyspnea Severity

    Dyspnea severity will be assessed in patients following open heart surgery using a standardized dyspnea assessment scale. Changes in dyspnea scores will be evaluated and compared between the Bubble-PEP intervention group and the control group. Higher scores will indicate greater dyspnea severity.

    Time frame: Days 1, 2, and 3 post-extubation

  8. Change in Respiratory Secretion Status

    Respiratory secretion status will be assessed in patients following open heart surgery to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on airway secretion clearance. Changes in secretion status will be evaluated and compared between the intervention and control groups.

    Time frame: Days 1, 2, and 3 post-extubation

Secondary outcomes

  1. Change in Postoperative Pain Intensity

    Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores will be compared between the Bubble-PEP intervention group and the control group.

    Time frame: Days 1, 2, and 3 post-extubation

07

Study locations

1 site
08

References and documents

Publications

  • Pieczkoski SM, de Oliveira AL, Haeffner MP, Azambuja ACM, Sbruzzi G. Positive expiratory pressure in postoperative cardiac patients in intensive care: A randomized controlled trial. Clin Rehabil. 2021 May;35(5):681-691. doi: 10.1177/0269215520972701. Epub 2020 Nov 24. PubMed 33233946 ↗
  • Santos MD, Milross MA, McKenzie DK, Alison JA. Bubble-positive expiratory pressure device and sputum clearance in bronchiectasis: A randomised cross-over study. Physiother Res Int. 2020 Jul;25(3):e1836. doi: 10.1002/pri.1836. Epub 2020 Feb 29. PubMed 32113192 ↗
  • OMNIA, M. N., FATMA, S., GHADA, A. A., & ISMAIL, M. (2024). Efficacy of Bubble Positive Expiratory Pressure Device in Post Thoracic Surgery Patients. The Medical Journal of Cairo University, 92(03), 119-127.

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available or shared with other researchers. The study involves patients undergoing open-heart surgery, and participant confidentiality and data privacy will be maintained in accordance with the approved research protocol and applicable ethical and data protection requirements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2027, 4 months later.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Aug 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945483
Responsible party
Hamide Erkan (Research Assistant, Afyonkarahisar Health Sciences University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Hamide N Erkan, Research Assistant
Contact
hamidenurerkan@gmail.com
05418573326

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion